Press Releases

April 7 2014

The EXPIRE Act would extend tax credits that expired at the end of 2013, including...

September 30 2013

NSF-funded companies focused on drug discovery, diagnostics and other platform technologies....

September 11 2013

Speakers will provide fresh insight, investment opportunities in biotech sector.

July 10 2013

Chimerix President and CEO emphasizes the role of the public market to help finance critical R...

June 6 2012

The report will be released at a Super Session, titled "International Leaders Share Their...

April 5 2012

The Biotechnology Industry Organization expressed strong support for the signing of the...

March 22 2012

The Biotechnology Industry Organization (BIO) applauds the Senate on the passage of H.R. 3606...

December 6 2011

Washington, DC (December 6, 2011) – The Biotechnology Industry Organization (BIO)...

November 16 2011

"The most important return on investment from this initiative would be the creation of...

November 2 2011

The Small Company Capital Formation Act (HR 1070) passed today by a vote of 421-1.

October 13 2011

BIO President and CEO Jim Greenwood released the following statement on the Obama...

September 16 2011

BIO President and CEO Jim Greenwood released the following statement on President Obama's...

April 7 2011

Today, the House Subcommittee on Healthcare and Technology will hold a hearing on The Creating...

January 3 2011

The 2011 BIO International Convention will highlight the latest trends and the newest...

October 15 2009

The Biotechnology Industry Organization (BIO) today announced Plenary Session and Business...

June 26 2007

Today, the House Science and Technology Committee’s Technology and Innovation Subcommittee will...

July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
March 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth across the country.
December 1 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of implementing policies that will spur job growth through capital formation while protecting investors.  
July 31 2014
Washington, D.C. (July 31, 2014) – The Biotechnology Industry Organization (BIO) today encourages support for the Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation (COMPETE) Act, introduced today by Senator Tom Carper (D-DE). 
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.
September 30 2013
NSF-funded companies focused on drug discovery, diagnostics and other platform technologies.
September 11 2013
Speakers will provide fresh insight, investment opportunities in biotech sector.
July 10 2013
Chimerix President and CEO emphasizes the role of the public market to help finance critical R&D.